Nevens, Frederik http://orcid.org/0000-0002-4268-5736
Bittencourt, Paulo Lisboa
Coenraad, Minneke J.
Ding, Huiguo
Hou, Ming-Chih
Laterre, Pierre-François
Mendizabal, Manuel
Ortiz-Olvera, Nayeli Xochiquetzal
Vorobioff, Julio D.
Zhang, Wenhong
Angeli, Paolo
Funding for this research was provided by:
Ferring Pharmaceuticals
Article History
Received: 20 April 2018
Accepted: 29 December 2018
First Online: 25 January 2019
Compliance with ethical standards
:
: Frederik Nevens has received a consultancy grant from Ferring. Manuel Mendizabal has received payments for lectures from Bristol-Myers Squibb, AbbVie, Gilead, Ferring and Bayer; honoraria for consulting from Ferring and Gilead. Paolo Angeli declares the following: 2014–2018: Sequana Medical AG Advisory Board; 2016–2018: Biovie Advisory Board and patent application; 2016 Gilead (Italy): Advisory board and grant; 2014 Bhering: travel grant; 2016 Kedrion: speaker invitation. Paulo Lisboa Bittencourt, Minneke J Coenraad, Huiguo Ding, Ming-Chih Hou, Pierre-François Laterre, Nayeli Xochiquetzal Ortiz-Olvera, Julio D. Vorobioff, Wenhong Zhang declare that they have no conflict of interest.